286 related articles for article (PubMed ID: 25620544)
1. Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic.
Wahner Hendrickson AE; Hawthorne KM; Goode EL; Kalli KR; Goergen KM; Bakkum-Gamez JN; Cliby WA; Keeney GL; Visscher DW; Tarabishy Y; Oberg AL; Hartmann LC; Maurer MJ
Gynecol Oncol; 2015 Apr; 137(1):77-85. PubMed ID: 25620544
[TBL] [Abstract][Full Text] [Related]
2. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
3. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
4. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
Rauh-Hain JA; Foley OW; Winograd D; Andrade C; Clark RM; Vargas RJ; Hinchcliff EM; Esselen KM; Horowitz NS; del Carmen MG
Am J Obstet Gynecol; 2015 May; 212(5):600.e1-8. PubMed ID: 25514761
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer.
Eng KH; Morrell K; Starbuck K; Spring-Robinson C; Khan A; Cleason D; Akman L; Zsiros E; Odunsi K; Szender JB
Gynecol Oncol; 2017 Jul; 146(1):52-57. PubMed ID: 28495239
[TBL] [Abstract][Full Text] [Related]
7. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
[TBL] [Abstract][Full Text] [Related]
8. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA
Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
[TBL] [Abstract][Full Text] [Related]
10. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.
Fagotti A; Vizzielli G; Fanfani F; Costantini B; Ferrandina G; Gallotta V; Gueli Alletti S; Tortorella L; Scambia G
Gynecol Oncol; 2013 Nov; 131(2):341-6. PubMed ID: 23938372
[TBL] [Abstract][Full Text] [Related]
11. The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
Zhu J; Wang H; Liu CC; Lu Y; Tang H
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2339-45. PubMed ID: 27566683
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of early versus late onset of bone metastasis in patients with carcinoma of the ovary, peritoneum and fallopian tube.
Sehouli J; Olschewski J; Schotters V; Fotopoulou C; Pietzner K
Ann Oncol; 2013 Dec; 24(12):3024-8. PubMed ID: 24130264
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
Ebata T; Yunokawa M; Yoshida H; Bun S; Shimoi T; Shimomura A; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
Int J Gynecol Cancer; 2017 Nov; 27(9):1850-1855. PubMed ID: 29040183
[TBL] [Abstract][Full Text] [Related]
15. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
Timmermans M; van der Aa MA; Lalisang RI; Witteveen PO; Van de Vijver KK; Kruitwagen RF; Sonke GS
Gynecol Oncol; 2018 Sep; 150(3):446-450. PubMed ID: 30001834
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
17. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Pérez-Milán F; Ortiz-Quintana L
Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
[TBL] [Abstract][Full Text] [Related]
18. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.
Ataseven B; Grimm C; Harter P; Heitz F; Traut A; Prader S; du Bois A
Gynecol Oncol; 2016 Feb; 140(2):215-20. PubMed ID: 26691222
[TBL] [Abstract][Full Text] [Related]
20. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]